Harten Group

Search form

Harten Group is one of Europe’s leading providers of specialist consultancy support for the pharmaceutical and biotech industries.

We offer flexible solutions to meet specific needs, ranging from sourcing individual interim managers, putting together a multi-disciplinary team or carrying out a permanent recruitment search.

Our company which has been established since 1995, has over 2000 highly qualified specialists on its network. This enables rapid response to requirements mostly in the UK and Europe but also globally.

On average our consultants have over ten years of industry experience gained across a diverse range of areas. This bank of expertise can be harnessed in many different ways, from the recruitment of a single consultant on a contract basis, fielding a team of consultants to address a bigger challenge or finding a permanent employee.

Advertisements in Pipeline

Harten Group is highlighting its significant expertise in the area of pharmacovigilance by placing advertisements in Pipeline magazine, the official publication for the Pharmaceutical Information & Pharmacovigilance Association. The ad focuses on Harten Group's capability in terms of providing interim QPPVs, pharmaceutical physicians and senior drug safety managers to the industry. The first ad appeared in the December issue; the second in March, accompanied by an article giving the inside track on PV inspections and the third ad will appear in June. Further information >>

Latest assignments

Interim EU QP (PV)

6-12 Months

Oncology Medical Director

Interim or Permanent

Interim Quality Assurance

3-6 Months

Recent projects & updates

A consultant has been helping a generics company headquartered in Ireland, currently branching into branded pharmaceuticals, with training and raising awareness of the Code to ensure local and UK compliance.

Harten Group consultant handles all regulatory requirements for compiling and submitting monthly safety updates for a global pharma company's antiviral during recent flu epidemic.

Read full details >>